Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

[Answer to the letter to the editor: "Comments on generic antibiotics"].

Gauzit R, Petitjean O.

Med Mal Infect. 2013 Jan;43(1):36-7. doi: 10.1016/j.medmal.2012.11.002. Epub 2013 Jan 29. French. No abstract available.

PMID:
23375016
2.

Animal model methodology: immunocompetent or leucopenic rats, which is the best? Results from a model of experimental pneumonia due to derepressed cephalosporinase-producing Enterobacter cloacae.

Jacolot A, Judel C, Chaumais MC, Louchahi K, Nicolas P, Marchand S, Petitjean O, Mimoz O.

Chemotherapy. 2012;58(2):129-33. doi: 10.1159/000337061. Epub 2012 May 10.

PMID:
22572147
3.

How to solve the problem of spontaneous bacterial clearance when testing new antibiotic treatment: results on experimental pneumonia due to a derepressed cephalosporinase-producing Enterobacter cloacae.

Jacolot A, Judel C, Louchahi K, Tod M, Marchand S, Petitjean O, Mimoz O.

Fundam Clin Pharmacol. 2013 Jun;27(3):239-43. doi: 10.1111/j.1472-8206.2012.01026.x. Epub 2012 Jan 29.

PMID:
22283475
4.

Nebulized and intravenous colistin in experimental pneumonia caused by Pseudomonas aeruginosa.

Lu Q, Girardi C, Zhang M, Bouhemad B, Louchahi K, Petitjean O, Wallet F, Becquemin MH, Le Naour G, Marquette CH, Rouby JJ.

Intensive Care Med. 2010 Jul;36(7):1147-55. doi: 10.1007/s00134-010-1879-4. Epub 2010 Apr 16.

PMID:
20397007
5.

Nebulized ceftazidime in experimental pneumonia caused by partially resistant Pseudomonas aeruginosa.

Ferrari F, Lu Q, Girardi C, Petitjean O, Marquette CH, Wallet F, Rouby JJ; Experimental ICU Study Group.

Intensive Care Med. 2009 Oct;35(10):1792-800. doi: 10.1007/s00134-009-1605-2. Epub 2009 Aug 4.

PMID:
19652947
6.

Acetazolamide for Monge's disease: efficiency and tolerance of 6-month treatment.

Richalet JP, Rivera-Ch M, Maignan M, Privat C, Pham I, Macarlupu JL, Petitjean O, León-Velarde F.

Am J Respir Crit Care Med. 2008 Jun 15;177(12):1370-6. doi: 10.1164/rccm.200802-196OC. Epub 2008 Apr 3.

PMID:
18388356
7.

Acetazolamide: a treatment for chronic mountain sickness.

Richalet JP, Rivera M, Bouchet P, Chirinos E, Onnen I, Petitjean O, Bienvenu A, Lasne F, Moutereau S, León-Velarde F.

Am J Respir Crit Care Med. 2005 Dec 1;172(11):1427-33. Epub 2005 Aug 26.

PMID:
16126936
8.

Comparison of 99mTc-DTPA and urea for measuring cefepime concentrations in epithelial lining fluid.

Bayat S, Louchahi K, Verdière B, Anglade D, Rahoui A, Sorin PM, Tod M, Petitjean O, Fraisse F, Grimbert FA.

Eur Respir J. 2004 Jul;24(1):150-6.

9.

Differential diffusions of indinavir and lopinavir in genital secretions of human immunodeficiency virus-infected women.

Launay O, Tod M, Louchahi K, Belarbi L, Bouchaud O, Mémain N, Petitjean O, Robineau M, Guillevin L, Lortholary O.

Antimicrob Agents Chemother. 2004 Feb;48(2):632-4.

10.

Efficacy of beta-lactams for treating experimentally induced pneumonia due to a carbapenem-hydrolyzing metallo-beta-lactamase-producing strain of Pseudomonas aeruginosa.

Bellais S, Mimoz O, Léotard S, Jacolot A, Petitjean O, Nordmann P.

Antimicrob Agents Chemother. 2002 Jun;46(6):2032-4.

11.

Pharmacokinetics of teicoplanin during plasma exchange.

Alet P, Lortholary O, Fauvelle F, Tod M, Genereau T, Louchahi M, Leon A, Guillevin L, Petitjean O.

Clin Microbiol Infect. 1999 Apr;5(4):213-218.

12.

Antimicrobial susceptibility test: from bacterial population analysis to therapy.

Scavizzi MR, Labia R, Petitjean OJ, Elbhar A.

Int J Antimicrob Agents. 2002 Jan;19(1):9-20.

PMID:
11814763
13.

Estimation of pharmacokinetic parameters by orthogonal regression: comparison of four algorithms.

Tod M, Aouimer A, Petitjean O.

Comput Methods Programs Biomed. 2002 Jan;67(1):13-26.

PMID:
11750944
14.
15.

Co-amoxiclav pharmacokinetics during posttraumatic hemorrhagic shock.

Mimoz O, Schaeffer V, Incagnoli P, Louchahi K, Edouard A, Petitjean O, Tod M.

Crit Care Med. 2001 Jul;29(7):1350-5.

PMID:
11445684
17.

Pharmacokinetics of oral acyclovir in neonates and in infants: a population analysis.

Tod M, Lokiec F, Bidault R, De Bony F, Petitjean O, Aujard Y.

Antimicrob Agents Chemother. 2001 Jan;45(1):150-7.

18.
19.

Clinical pharmacokinetics during plasma exchange.

Fauvelle F, Petitjean O, Tod M, Guillevin L.

Therapie. 2000 Mar-Apr;55(2):269-75. Review.

PMID:
10967699
20.

Clinical pharmacokinetics and pharmacodynamics of isepamicin.

Tod M, Padoin C, Petitjean O.

Clin Pharmacokinet. 2000 Mar;38(3):205-23. Review.

PMID:
10749517
21.
22.

Isepamicin in intensive care unit patients with nosocomial pneumonia: population pharmacokinetic-pharmacodynamic study.

Tod M, Minozzi C, Beaucaire G, Ponsonnet D, Cougnard J, Petitjean O.

J Antimicrob Chemother. 1999 Jul;44(1):99-108.

PMID:
10459816
23.

Treatment of experimental pneumonia in rats caused by a PER-1 extended-spectrum beta-lactamase-producing strain of Pseudomonas aeruginosa.

Mimoz O, Elhelali N, Léotard S, Jacolot A, Laurent F, Samii K, Petitjean O, Nordmann P.

J Antimicrob Chemother. 1999 Jul;44(1):91-7.

PMID:
10459815
24.

Fluconazole, with or without dexamethasone for experimental cryptococcosis: impact of treatment timing.

Lortholary O, Nicolas M, Soreda S, Improvisi L, Ronin O, Petitjean O, Dupont B, Tod M, Dromer F.

J Antimicrob Chemother. 1999 Jun;43(6):817-24.

PMID:
10404321
25.

Pharmacokinetics of cefpirome during the posttraumatic systemic inflammatory response syndrome.

Jacolot A, Incagnoli P, Edouard AR, Tod M, Petitjean O, Samii K, Mimoz O.

Intensive Care Med. 1999 May;25(5):486-91.

PMID:
10401943
26.

Pharmacokinetics and absolute bioavailability of ciprofloxacin administered through a nasogastric tube with continuous enteral feeding to critically ill patients.

Mimoz O, Binter V, Jacolot A, Edouard A, Tod M, Petitjean O, Samii K.

Intensive Care Med. 1998 Oct;24(10):1047-51.

PMID:
9840238
27.

Clinical pharmacokinetics of diacerein.

Nicolas P, Tod M, Padoin C, Petitjean O.

Clin Pharmacokinet. 1998 Nov;35(5):347-59. Review.

PMID:
9839088
28.
29.

[Pharmocokinetics of ciprofloxacine].

Petitjean O.

Presse Med. 1998 Apr 11;27(14):690-2. Review. French. No abstract available.

PMID:
9767931
30.

Implementation and evaluation of a stochastic control strategy for individualizing teicoplanin dosage regimen.

Tod M, Alet P, Lortholary O, Petitjean O.

J Pharmacokinet Biopharm. 1997 Dec;25(6):695-712.

PMID:
9697078
31.

Analysis of the pharmacokinetic interaction between cephalexin and quinapril by a nonlinear mixed-effect model.

Padoin C, Tod M, Perret G, Petitjean O.

Antimicrob Agents Chemother. 1998 Jun;42(6):1463-9.

32.

Cefepime and amikacin synergy in vitro and in vivo against a ceftazidime-resistant strain of Enterobacter cloacae.

Mimoz O, Jacolot A, Padoin C, Tod M, Samii K, Petitjean O.

J Antimicrob Chemother. 1998 Mar;41(3):367-72.

PMID:
9578163
33.

Population pharmacokinetic study of amikacin administered once or twice daily to febrile, severely neutropenic adults.

Tod M, Lortholary O, Seytre D, Semaoun R, Uzzan B, Guillevin L, Casassus P, Petitjean O.

Antimicrob Agents Chemother. 1998 Apr;42(4):849-56.

34.

Cefepime and amikacin synergy against a cefotaxime-susceptible strain of Enterobacter cloacae in vitro and in vivo.

Mimoz O, Jacolot A, Padoin C, Caillon J, Louchahi K, Tod M, Samii K, Petitjean O.

J Antimicrob Chemother. 1997 Mar;39(3):363-9.

PMID:
9096186
35.

Monitoring of 8-methoxypsoralen during extracorporeal photochemotherapy: evidence for a "first-dose" effect.

Jacolot A, Tod M, Heudes AM, Petitjean O, Laroche L.

Ther Drug Monit. 1996 Jun;18(3):234-9.

PMID:
8738761
36.

Population pharmacokinetic study of teicoplanin in severely neutropenic patients.

Lortholary O, Tod M, Rizzo N, Padoin C, Biard O, Casassus P, Guillevin L, Petitjean O.

Antimicrob Agents Chemother. 1996 May;40(5):1242-7.

37.

Population pharmacokinetic study of isepamicin with intensive care unit patients.

Tod M, Padoin C, Minozzi C, Cougnard J, Petitjean O.

Antimicrob Agents Chemother. 1996 Apr;40(4):983-7.

38.

Pharmacokinetic interaction between cefdinir and two angiotensin-converting enzyme inhibitors in rats.

Jacolot A, Tod M, Petitjean O.

Antimicrob Agents Chemother. 1996 Apr;40(4):979-82.

39.

Malignant ventricular arrhythmia during treatment with terfenadine and itraconazole: A pharmacokinetic study.

Lortholary O, Rizzo N, Tod M, Artigou JY, Beaudreuil J, Cohen Y, Casassus P, Petitjean O.

Clin Microbiol Infect. 1996 Mar;1(3):209-211. No abstract available.

40.

Influence of experimental rat model of multiple organ dysfunction on cefepime and amikacin pharmacokinetics.

Mimoz O, Jacolot A, Padoin C, Quillard J, Tod M, Louchahi K, Samii K, Petitjean O.

Antimicrob Agents Chemother. 1996 Mar;40(3):819-21.

41.

Assessment of two penicillins plus beta-lactamase inhibitors versus cefotaxime in treatment of murine Klebsiella pneumoniae infections.

Fournier JL, Ramisse F, Jacolot AC, Szatanik M, Petitjean OJ, Alonso JM, Scavizzi MR.

Antimicrob Agents Chemother. 1996 Feb;40(2):325-30. Erratum in: Antimicrob Agents Chemother 1996 Oct;40(10):2441.

42.

A population pharmacokinetic study of alminoprofen penetration into synovial fluid.

Tod M, Pobel C, Le Gros V, Louchahi K, Petitjean O, Brion N, Garcia-Mace JL.

Biopharm Drug Dispos. 1995 Nov;16(8):627-34.

PMID:
8573683
43.

Aminoglycosides.

Lortholary O, Tod M, Cohen Y, Petitjean O.

Med Clin North Am. 1995 Jul;79(4):761-87. Review.

PMID:
7791422
44.

Influence of methodological aspects on tissue drug concentration estimation.

Petitjean O, Tod M, Louchahi K.

J Pharm Biomed Anal. 1995 Jun;13(7):817-22.

PMID:
8562604
45.

Fluconazole penetration in cerebral parenchyma in humans at steady state.

Thaler F, Bernard B, Tod M, Jedynak CP, Petitjean O, Derome P, Loirat P.

Antimicrob Agents Chemother. 1995 May;39(5):1154-6.

46.

Pharmacokinetics of amoxicillin coadministered with a saline-polyethylene glycol solution in healthy volunteers.

Padoin C, Tod M, Brion N, Louchahi K, Le Gros V, Petitjean O.

Biopharm Drug Dispos. 1995 Apr;16(3):169-76.

PMID:
7787129
47.

Time- and dose-dependent kinetics of all-trans-retinoic acid in rats after oral or intravenous administration(s).

el Mansouri S, Tod M, Leclerq M, Petitjean O, Perret G, Porthault M.

Drug Metab Dispos. 1995 Feb;23(2):227-31.

PMID:
7736916
48.

Determination of piracetam in human plasma and urine by liquid chromatography.

Louchahi K, Tod M, Bonnardel P, Petitjean O.

J Chromatogr B Biomed Appl. 1995 Jan 20;663(2):385-9.

PMID:
7735487
49.

Drug interaction and pharmacological considerations during anti-infective therapy in cancer patients.

Petitjean O, Nicolas P, Tod M.

Cancer Treat Res. 1995;79:255-80. Review. No abstract available.

PMID:
8746659
50.

Cellular localisations of interleukin-1 beta, interleukin-6 and tumor necrosis factor-alpha mRNA in a parasitic granulomatous disease of the liver, alveolar echinococcosis.

Bresson-Hadni S, Petitjean O, Monnot-Jacquard B, Heyd B, Kantelip B, Deschaseaux M, Racadot E, Vuitton DA.

Eur Cytokine Netw. 1994 Sep-Oct;5(5):461-8.

PMID:
7880977

Supplemental Content

Loading ...
Support Center